Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NYSE:ARA

American Renal Associates (ARA) Stock Price, News & Analysis

American Renal Associates logo

About American Renal Associates Stock (NYSE:ARA)

Key Stats

Today's Range
$11.33
$11.52
50-Day Range
$11.46
$11.52
52-Week Range
$5.57
$11.98
Volume
9,831 shs
Average Volume
106,940 shs
Market Capitalization
$397.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Receive ARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for American Renal Associates and its competitors with MarketBeat's FREE daily newsletter.

ARA Stock News Headlines

Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
American Renal Associates Holdings, Inc. News
See More Headlines

ARA Stock Analysis - Frequently Asked Questions

American Renal Associates Holdings, Inc. (NYSE:ARA) issued its earnings results on Wednesday, November, 11th. The company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.09. The business had revenue of $209.69 million for the quarter, compared to the consensus estimate of $211.50 million. American Renal Associates had a negative net margin of 2.04% and a negative trailing twelve-month return on equity of 3.56%.

American Renal Associates (ARA) raised $161 million in an initial public offering (IPO) on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that American Renal Associates investors own include Zevra Therapeutics (KMPH), Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), Gilead Sciences (GILD), Spectrum Pharmaceuticals (SPPI), AbbVie (ABBV) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
11/11/2020
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous Health & Allied Services
Sub-Industry
N/A
Fax
N/A
Employees
4,977
Year Founded
N/A

Profitability

Net Income
$-13,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$822.52 million
Cash Flow
$1.69 per share
Book Value
$2.59 per share

Miscellaneous

Free Float
N/A
Market Cap
$397.94 million
Optionable
Optionable
Beta
1.11
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NYSE:ARA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners